Glecaprevir and pibrentasvir

(Mavyret®)

Glecaprevir and pibrentasvir

Drug updated on 11/13/2023

Dosage FormTablet (oral; 100 mg glecaprevir and 40 mg pibrentasvir); Pellets (oral; 50 mg glecaprevir and 20 mg pibrentasvir)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
  • For the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.